Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

tandard of care alone. Tumor Response was defined as Complete Response + Partial Response + Stable Disease at week 12 post-treatment, and there was no statistical significant difference between the groups (81% for SOC; 73% for TNFerade, p=0.5196). Surgical resections occurred in 15% of patients in the TNFerade + SOC group and 11% in the SOC group.

The safety analysis indicated that there was no statistically significant difference in the occurrence of serious adverse events, including thrombotic events, between the treatment and control groups. Seventy percent of patients receiving TNFerade + SOC and 78% of those receiving SOC alone had at least one serious adverse event. Eleven patients (33%) receiving TNFerade with SOC and seven patients (39%) receiving SOC alone had a protocol-defined thrombotic event. Adverse events associated with TNFerade were Grade 1 and 2 flu-like symptoms.

"ASCO has been the first opportunity to share in detail the data emerging from the PACT study," stated Mark Thornton, M.D., M.P.H., Ph.D., GenVec's Senior Vice President of Product Development. "Pancreatic cancer has been one of the most challenging oncology indications for drug developers. We are enthused by both the current safety profile of TNFerade, and the preliminary survival data of this agent in the setting of locally advanced pancreatic cancer. We anticipate discussing potential trial modifications with the FDA, and remain focused on advancing the PACT Study as expediently as possible," added Dr. Thornton.

The presented poster is available on the Company's website at www.genvec.com . To view the poster, click on the Investor Relations page, then follow the link to Webcasts and Data.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TN
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:6/2/2015)... 2015 The North American ... concerned market with analysis and forecast of revenue. ... 2014, and is estimated to reach $632.5 million ... 2014 to 2019. Browse through the ... an analysis of industry trends and segments, with ...
(Date:6/2/2015)... and Markets ( http://www.researchandmarkets.com/research/sn8mlw/picture_archiving ) has announced the addition of ... Strategic Business Report" report to their offering. ... Canada , Japan , ... Latin America , and Rest of World. ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/5tzcx6/specialty_enzymes ... Enzymes - Global Strategic Business Report" report to ... by the following End-Use Applications: Pharmaceutical & Diagnostics, Research/ ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Medicine Technology:North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Picture Archiving and Communication Systems (PACS) - Global Strategic Business Report 2015: User Demand Favors Integrated RIS/PACS Solutions 2Specialty Enzymes - Global Strategic Business Report 2015: Indispensable to the Pharmaceutical Industry 2
... (NYSE: WPI ), a leading integrated global pharmaceutical ... third quarter 2011 financial results on Tuesday, November 1, 2011 ... Company will also host a conference call and webcast at ... its financial results and provide an update on the Company,s ...
... (Nasdaq: PRGO ; TASE) today announced that Perrigo ... meet with analysts on Tuesday, September 27, 2011 at 8:00 ... Square, New York, NY.   The day will ... businesses, finance, sales and marketing, quality, and research and development. ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings 2
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 ZOOM+, ... of ZOOM+ Performance Health Insurance, announced today the opening ... Clean White 57 - a three-in-one complete dental exam, ... Clean Jr. for kids. Like all ZOOM+ services, ZOOM+Smile ... , “Why shouldn’t the dentist office be as inviting ...
(Date:6/2/2015)... June 02, 2015 Olive ... opening of Surrey’s first fertility clinic. Surrey ... a diverse, young community, with one of ... , Until now patients from Surrey ... to come into Vancouver or Burnaby for ...
(Date:6/2/2015)... 2015 TU-Automotive Detroit is the biggest ... 150+ speakers include senior execs from GM, Chrysler, Mercedes, ... provide a crucial status update on the automotive technology ... just 24 hours to secure one of the remaining ... wait for tomorrow. There are 70 sessions looking across ...
(Date:6/2/2015)... June 02, 2015 Vancouver, BC ... iData Research ( http://www.idataresearch.com ), the bone graft ... bone matrices (DBM) over traditional allograft materials. Because ... and thus an increase in operation time, alternative ... market growth in these synthetic materials is partly ...
(Date:6/2/2015)... National Autism Resource has partnered with ... development agency, to launch its new website and strategic ... new website is designed to help parents and ... autism. The site will expand its product line for ... from easy to understand information and helpful links to ...
Breaking Medicine News(10 mins):Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3
... Action Preserves Beneficiary Access to High Quality Nursing ... JOPLIN, Mo., Aug. 7 Citing the substantial,benefit ... to Protect Senior Care (CPSC) today thanked,Senator Susan ... effort,in Congress to stop the Bush Administration from ...
... Beneficiary Access to High Quality Nursing Home Care;,Helps ... Aug. 7 Citing the substantial,benefit in protecting ... Senior Care (CPSC) today thanked,Senator Elizabeth Dole for ... to stop the Bush Administration from moving forward ...
... 7 The dietary health of children is in,urgent ... only forward-thinking,convenient solutions with a line of fresh, healthy ... Most health guidelines recommend,children consume about 400 calories a ... the Public Interest, a consumer group based in Washington,D.C., ...
... Management, Inc. has a proven track record in supporting ... work with the U.S. Army,s Phase I/II clinical testing ... in Silver Spring, MD. CRM is the premier ... to expand its infectious disease capabilities, it looked to ...
... the next five ... Millennium Research Group, WALTHAM, Mass., Aug. 7 ... Health Imaging Systems 2008 report,the market for adjunct breast ... dedicated breast MRI systems, and,breast-specific gamma imaging (BSGI) systems ...
... with Toledo Children,s Hospital and Good Samaritan Hospital, ... NORTH HOLLYWOOD, Calif., Aug. 7 IPC ... leading national hospitalist,physician group practice company, announced today ... Children,s Hospital in Toledo,Ohio and Good Samaritan Hospital ...
Cached Medicine News:Health News:Senator Susan Collins Praised for Leading Successful Effort to Derail $4.3 Million Maine Medicare Cuts 2Health News:Senator Elizabeth Dole Praised for Leading Successful Effort to Derail $22.1 Million North Carolina Medicare Cuts 2Health News:Kidfresh Offers a Solution to the Rise of Unhealthy Eating Among Children With Fresh and Nutritious Prepared Meals for Kids 2Health News:Clinical Research Management gets contract for trials of therapeutics against infectious diseases 2Health News:Clinical Research Management gets contract for trials of therapeutics against infectious diseases 3Health News:Adjunct Breast Imaging Market to Increase by Almost 28% per Year Through 2013 2Health News:IPC The Hospitalist Company Enters Ohio and Pennsylvania Markets 2
Adjustable speed vortex with inter-changeable heads , 110 V...
Inquire...
Adjustable speed vortex with inter-changeable heads, 110 V...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Medicine Products: